In:
Science Immunology, American Association for the Advancement of Science (AAAS), Vol. 7, No. 71 ( 2022-05-27)
Abstract:
Many cancer therapies are limited by T cell exhaustion; thus, understanding the mechanisms by which T cells become exhausted in tumors is crucial for improving cancer therapies. Weisshaar et al. found that Rgs16, a regulator of G protein signaling, was linked to CD8 + T cell dysfunction and death in an Erk1-mediated manner in melanoma tumors. Knocking out Rgs16 rescued CD8 + T cell functionality and survival in tumors, leading to slower tumor growth and improving the efficacy of immune checkpoint blockade. Last, Rgs16 correlated to exhausted T cells and predicted poor responses to PD-1 blockade in patients with melanoma. Thus, Rgs16 regulates CD8 + T cell function in tumors and is a potential target to improve cancer therapies.
Type of Medium:
Online Resource
ISSN:
2470-9468
DOI:
10.1126/sciimmunol.abh1873
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Permalink